Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature
Journal of Antimicrobial Chemotherapy · 01.10.2024 · 79 (10) · 2421-2459
DOI: 10.1093/jac/dkae253 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 31.08.2024. Verfasst von David A Butler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA. Hauptthemen laut MEDLINE: Fosfomycin, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Drug Therapy, Combination. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 125 Literaturangaben. Gefördert von: Zavante Therapeutics, Inc., Delaware, USA.
Abstract (Originalsprache)
Treatment of patients with serious infections due to resistant Gram-negative bacteria remains highly problematic and has prompted clinicians to use existing antimicrobial agents in innovative ways. One approach gaining increased therapeutic use is combination therapy with IV fosfomycin. This article reviews the preclinical pharmacokinetic/pharmacodynamic (PK/PD) infection model and clinical data surrounding the use of combination therapy with IV fosfomycin for the treatment of serious infections caused by resistant Gram-negative bacteria. Data from dynamic in vitro and animal infection model studies of highly resistant Enterobacterales and non–lactose fermenters are positive and suggest IV fosfomycin in combination with a β-lactam, polymyxin or aminoglycoside produces a synergistic effect that rivals or surpasses that of other aminoglycoside- or polymyxin-containing regimens. Clinical studies performed to date primarily have involved patients with pneumonia and/or bacteraemia due to Klebsiella pneumoniae, Pseudomonas aeruginosa or Acinetobacter baumannii. Overall, the observed success rates with fosfomycin combination regimens were consistent with those reported for other combination regimens commonly used to treat these patients. In studies in which direct treatment comparisons can be derived, the results suggest that patients who received fosfomycin combination therapy had similar or improved outcomes compared with other therapies and combinations, especially when it was used in combination with a β-lactam that (1) targets PBP-3 and (2) has exceptional stability in the presence of β-lactamases. Collectively, the data indicate that combination therapy with IV fosfomycin should be considered as a potential alternative to aminoglycoside or polymyxin combinations for patients with antibiotic-resistant Gram-negative infections when benefits outweigh risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9255 Pharmacy Lane, La Jolla, CA, USA.
ORCID-Profile: David A Butler, Nimish Patel, J Nicholas O'Donnell, Thomas P Lodise
Förderung
- Zavante Therapeutics, Inc., Delaware, USA
Zitieren
APA
Butler, D. A., Patel, N., O'Donnell, J. N., & Lodise, T. P. (2024). Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature. Journal of Antimicrobial Chemotherapy, 79(10), 2421-2459. https://doi.org/10.1093/jac/dkae253
Vancouver
Butler DA, Patel N, O'Donnell JN, Lodise TP. Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature. Journal of Antimicrobial Chemotherapy. 2024;79(10):2421-2459. doi:10.1093/jac/dkae253
BibTeX
@article{Butler2024,
author = {Butler, David A and Patel, Nimish and O'Donnell, J Nicholas and Lodise, Thomas P},
title = {Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {10},
pages = {2421--2459},
doi = {10.1093/jac/dkae253}
}
EUVIMED